Liraglutide could reduce monthly migraine days
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research being presented at this year’s European Congress… read more.
Diet and exercise fail for most adults who try to lose weight in the long-term. Today the American Gastroenterological Association (AGA) released new evidence-based guidelines strongly recommending that these patients… read more.
Researchers at the Karolinska Institutet, University of Oxford and University of Copenhagen have shown that elevated levels of lipids known as ceramides can be associated with a ten-fold… read more.